Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Gummy Smile and Altered Passive Eruption Prevalence

NCT07548398 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-09-01
Last updated
2026-04-29

Condition(s) studied

Altered Passive Eruption of Teeth

Investigational drug(s) / intervention(s)

Clinical assessment

Clinical assessment: Non-invasive clinical evaluation including measurement of aesthetic indices (PES/WES), and intraoral photographic documentation.

Study summary

This observational epidemiological study aims to assess the prevalence of gummy smile and altered passive eruption in a young adult population, with a focus on the second sextant. Periodontal and aesthetic parameters, along with patient-reported discomfort, will be analyzed to identify potential correlations and underlying anatomical factors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male and female subjects; * Age between 18 and 50 years; * Periodontally healthy subjects; * Patients with no history of orthodontic treatment; * Patients without gingival hypertrophy or hyperplasia. Exclusion Criteria: * Age \< 18 or \> 50 years; * Patients diagnosed with Stage I-IV periodontitis; * Patients currently undergoing orthodontic treatment; * Patients with severe dental crowding in the second sextant; * Patients taking medications associated with gingival hypertrophy or -hyperplasia; * Patients unwilling to provide informed consent; * Patients with fixed or removable prostheses in the second sextant; * Patients with a history of surgical procedures in the second sextant; * Patients with uncontrolled diabetes or neuropsychiatric disorders; * Patients with infectious diseases; * Pregnant or breastfeeding women, or those with suspected pregnancy; * Patients taking bisphosphonates; * Oncologic patients and those undergoing head and neck radiotherapy or receiving chemotherapy; * Patients with alcohol or drug abuse.

Primary outcome measure(s)

  • Gingival display during smiling — Baseline (single visit)
    Quantitative assessment of gingival display during posed smile, measured as the vertical distance (in millimeters) between the inferior border of the upper lip and the gingival margin of the maxillary central incisors. Continuous variable (mm), measured using a calibrated periodontal probe and standardized intraoral photographs.
  • Prevalence of altered passive eruption (APE) — Baseline
    Assessment of the presence of altered passive eruption based on clinical crown dimensions and gingival margin position relative to anatomical landmarks. Measurement scale: Categorical variable (Presence/Absence)

Trial sites (1)

FacilityCityRegionStatus
Sapienza università di Roma Roma RM Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07548398 on ClinicalTrials.gov ↗ ← All trials in Italy